To obtain access to any datasets listed on this site, you must first receive approval from NIDA Datashare's Data Access Committee (DAC).

Please submit your request by sending your request to NIDA_Datashare_DAC@mail.nih.gov along with the following information:

  • Your name, title, and organization
  • Study Number and Study Title
  • The specific dataset(s) you are requesting
  • The intended use or purpose of the data
  • Willingness to comply with the NIDA Datashare Registration Agreement
Once your request is reviewed, you will receive instructions on how to proceed.

Thank you for your cooperation.

NIDA-CPU-0002

Division
DTMC
HEAL Study
No
Investigator(s)
Louis Cantilena, Jr., M.D, Ph.D.
Title
Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers
Short Description
To assess the safety, tolerance, and pharmacokinetics of multiple escalating dosages of oral GBR 12909 in cocaine experienced volunteers.
Release Date
May 23, 2017
Description

This is a human laboratory study that will assess the clinical pharmacology, safety and tolerance of three escalating oral doses of GBR 12909, which is 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride, in cocaine experienced volunteers.

Keywords
cocaine
gbr12909
interaction
phase 1a
stimulant
Assessments
Addiction Research Center Inventory
Blood Study Agent Level
Brief Substance Craving Scale
Change in Sexual Function Questionnaire
ECG Monitoring
McLean Hospital Event Overt Aggression Checklist
Systematic Assessment for Treatment Emergent Effects
Vital Signs Monitoring
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Links
ClinicalTrials.gov Link
CPU-0002 in NIH clinical trials registry